Epigral targets ₹5,000 crore revenue by FY31 on capacity expansion

Epigral, a leading specialty chemicals producer, is pursuing an ambitious growth roadmap centred on expanding production capacity for two core products. Chairman and Managing Director Maulik Patel said the company ended FY26 with revenue of ₹2,500-2,530 crore and projects ₹2,900 crore for the current financial year at its current growth trajectory.

The company is doubling its CPVC Resin production capacity from 75,000 tonnes per annum (TPA) to 1,50,000 TPA, while simultaneously doubling Epichlorohydrin (ECH) capacity from 50,000 TPA to 1,00,000 TPA at its existing manufacturing facilities in Dahej, Gujarat. These capacity enhancements are expected to commence contributing to revenues from the next financial year onwards.

"The capacity increase in production of CPVC Resin and ECH will start adding to the revenue from next year. Therefore, we are expecting to double our revenue to around ₹5,000 crore by 2030-31," Patel told industry observers. The expansion represents a significant bet on growing demand for these specialty chemical products across India's manufacturing and construction sectors.

The scale-up of both product lines at the company's Dahej operations underscores Epigral's strategy to strengthen its position in high-demand specialty chemicals segments. The phased capacity additions are designed to meet rising consumption while leveraging existing infrastructure and operational expertise at the Gujarat facility.